Literature DB >> 18253831

Oxidative stress, inflammation and neutrophil superoxide release in patients with Crohn's disease: distinction between active and non-active disease.

Irit Maor1, Tova Rainis, Amos Lanir, Alexandra Lavy.   

Abstract

Increased oxidative stress has been previously demonstrated in patients with Crohn's disease (CD). However, to date, this parameter has not been assessed in a comparative study of patients in prolonged remission and those with the active disease. We report here our study of lipid peroxidation, antioxidant and inflammation status in serum derived from 16 active CD patients, 27 clinically stable patients, and 15 healthy controls. Results The extent of lipid peroxidation was higher in CD patients than in the healthy controls, while the levels of lipid peroxides (PD) and of thiobarbituric acid-reactive substances (TBARS) were significantly (P < 0.01) higher in serum obtained from patients with active CD (22 and 30%, respectively) than in that obtained from patients in remission. An analysis of the antioxidant status revealed that the beta-carotene levels in sera derived from all CD patients - patients with active or stable CD (49.4 +/- 15 and 95.6 +/- 25 mg% beta-carotene, respectively) - were higher than that in the controls (145 +/- 40 mg%). Serum activity of glutathione peroxidase (GSH-Px) was significantly (P < 0.001) higher (by 31%) in the patients with active CD than in the control group. There was no significant difference in GSH-Px activity between patients in remission and the controls. In terms of the inflammatory status, we found significantly (P < 0.01) higher levels of C-reactive proteins (CRP) and of tumor necrosis factor alpha (TNFalpha) in patients with active CD than in CD patients in remission. There was a significant correlation between those parameters and the extent of lipid oxidation. Neutrophils, which are a potential source of oxygen-free radicals, were activated by incubation with phorbol myristate acetate (PMA). Superoxide and lysozyme release were significantly reduced in neutrophils derived from patients with active CD (by 25 and 28%, respectively) in comparison to the control group. However, stimulated neutrophils from stable patients demonstrated only a minimally non-significant lower release of superoxide and lysozyme compared to the controls. Conclusion The results obtained in this study demonstrate an enhanced inflammatory and oxidative stress and a decreased antioxidant status in patients with active CD. As the patients improved and became clinically stable, the oxidative parameters decreased, approaching normal values. As neutrophil activation was also lower in patients with active disease, neutrophil activation may represent a possible defense mechanism of the body against tissue injury.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18253831     DOI: 10.1007/s10620-007-0141-6

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  30 in total

1.  Altered lipid profile, lipoprotein composition, and oxidant and antioxidant status in pediatric Crohn disease.

Authors:  E Levy; Y Rizwan; L Thibault; G Lepage; S Brunet; L Bouthillier; E Seidman
Journal:  Am J Clin Nutr       Date:  2000-03       Impact factor: 7.045

Review 2.  Management of Crohn's disease in adults.

Authors:  S B Hanauer; S Meyers
Journal:  Am J Gastroenterol       Date:  1997-04       Impact factor: 10.864

3.  Automated determination of lysozyme activities in biological fluids.

Authors:  J A Navarro Gonzalvez; J A Manzanos Arnaiz; C Garcia Benayas; I Vidriales Vicente; J Arenas
Journal:  Clin Chem       Date:  1993-01       Impact factor: 8.327

Review 4.  Free-radical mechanisms in tissue injury.

Authors:  T F Slater
Journal:  Biochem J       Date:  1984-08-15       Impact factor: 3.857

Review 5.  Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease.

Authors:  R B Sartor
Journal:  Gastroenterol Clin North Am       Date:  1995-09       Impact factor: 3.806

6.  Altered ascorbic acid status in the mucosa from inflammatory bowel disease patients.

Authors:  G D Buffinton; W F Doe
Journal:  Free Radic Res       Date:  1995-02

7.  Superoxide production by Crohn's disease neutrophils.

Authors:  F T Curran; R N Allan; M R Keighley
Journal:  Gut       Date:  1991-04       Impact factor: 23.059

8.  Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease.

Authors:  S Schreiber; T Heinig; H G Thiele; A Raedler
Journal:  Gastroenterology       Date:  1995-05       Impact factor: 22.682

9.  Diminished neutrophil function in Crohn's disease and ulcerative colitis identified by decreased oxidative metabolism and low superoxide dismutase content.

Authors:  H W Verspaget; A S Peña; I T Weterman; C B Lamers
Journal:  Gut       Date:  1988-02       Impact factor: 23.059

10.  Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease.

Authors:  J M Reimund; C Wittersheim; S Dumont; C D Muller; R Baumann; P Poindron; B Duclos
Journal:  J Clin Immunol       Date:  1996-05       Impact factor: 8.317

View more
  17 in total

1.  The neutrophil respiratory burst and bacterial digestion in Crohn's disease.

Authors:  Levent Filik
Journal:  Dig Dis Sci       Date:  2011-06       Impact factor: 3.199

2.  The effects of an oral supplement enriched with fish oil, prebiotics, and antioxidants on nutrition status in Crohn's disease patients.

Authors:  Dawn M Wiese; Bret A Lashner; Edith Lerner; Stephen J DeMichele; Douglas L Seidner
Journal:  Nutr Clin Pract       Date:  2011-08       Impact factor: 3.080

3.  Different profile of peripheral antioxidant enzymes and lipid peroxidation in active and non-active inflammatory bowel disease patients.

Authors:  D Achitei; A Ciobica; G Balan; E Gologan; C Stanciu; G Stefanescu
Journal:  Dig Dis Sci       Date:  2013-01-11       Impact factor: 3.199

Review 4.  Oxidative stress: an essential factor in the pathogenesis of gastrointestinal mucosal diseases.

Authors:  Asima Bhattacharyya; Ranajoy Chattopadhyay; Sankar Mitra; Sheila E Crowe
Journal:  Physiol Rev       Date:  2014-04       Impact factor: 37.312

5.  Iron requirements based upon iron absorption tests are poorly predicted by haematological indices in patients with inactive inflammatory bowel disease.

Authors:  Miranda C E Lomer; William B Cook; Hamid Jan B Jan-Mohamed; Carol Hutchinson; Ding Yong Liu; Robert C Hider; Jonathan J Powell
Journal:  Br J Nutr       Date:  2011-12-09       Impact factor: 3.718

6.  Characterization of Serum Cytokine Profile in Predominantly Colonic Inflammatory Bowel Disease to Delineate Ulcerative and Crohn's Colitides.

Authors:  Olga Y Korolkova; Jeremy N Myers; Samuel T Pellom; Li Wang; Amosy E M'Koma
Journal:  Clin Med Insights Gastroenterol       Date:  2015-05-06

7.  Methyl deficient diet aggravates experimental colitis in rats.

Authors:  Min Chen; Laurent Peyrin-Biroulet; Amandine George; Florence Coste; Aude Bressenot; Carine Bossenmeyer-Pourie; Jean-Marc Alberto; Bing Xia; Bernard Namour; Jean-Louis Guéant
Journal:  J Cell Mol Med       Date:  2011-11       Impact factor: 5.310

Review 8.  Review article: the role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases.

Authors:  Aleksandra Piechota-Polanczyk; Jakub Fichna
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-05-06       Impact factor: 3.000

Review 9.  Impact of Cigarette Smoking on the Gastrointestinal Tract Inflammation: Opposing Effects in Crohn's Disease and Ulcerative Colitis.

Authors:  Loni Berkowitz; Bárbara M Schultz; Geraldyne A Salazar; Catalina Pardo-Roa; Valentina P Sebastián; Manuel M Álvarez-Lobos; Susan M Bueno
Journal:  Front Immunol       Date:  2018-01-30       Impact factor: 7.561

Review 10.  Possible Biomarkers in Blood for Crohn's Disease: Oxidative Stress and MicroRNAs-Current Evidences and Further Aspects to Unravel.

Authors:  Inés Moret-Tatay; Marisa Iborra; Elena Cerrillo; Luis Tortosa; Pilar Nos; Belén Beltrán
Journal:  Oxid Med Cell Longev       Date:  2015-12-28       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.